Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein
D Van Egeren, A Novokhodko, M Stoddard, U Tran… - medRxiv, 2020 - medrxiv.org
As many prophylactics targeting SARS-CoV-2 are aimed at the spike protein receptor-
binding domain (RBD), we examined the risk of immune evasion from previously published …
binding domain (RBD), we examined the risk of immune evasion from previously published …
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain
or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies …
or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies …
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …
Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2
With the recent spread of severe acute respiratory syndrome coronavirus (SARS-CoV-2) _
infecting> 16 million people worldwide as of 28 July 2020, causing> 650 000 deaths, there …
infecting> 16 million people worldwide as of 28 July 2020, causing> 650 000 deaths, there …
[HTML][HTML] The antigenic anatomy of SARS-CoV-2 receptor binding domain
Antibodies are crucial to immune protection against SARS-CoV-2, with some in emergency
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …
use as therapeutics. Here, we identify 377 human monoclonal antibodies (mAbs) …
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions
E Gavor, YK Choong, SY Er, H Sivaraman… - Trends in …, 2020 - cell.com
The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …
Potent NTD-targeting neutralizing antibodies against SARS-CoV-2 selected from a synthetic immune system
W Li, F Wang, Y Li, L Yan, L Liu, W Zhu, P Ma, X Shi… - Vaccines, 2023 - mdpi.com
The majority of neutralizing antibodies (NAbs) against SARS-CoV-2 recognize the receptor-
binding domain (RBD) of the spike (S) protein. As an escaping strategy, the RBD of the virus …
binding domain (RBD) of the spike (S) protein. As an escaping strategy, the RBD of the virus …